









Markets
/
Stocks
/
nasdaq-lenz
/

LENZ Therapeutics Inc

LENZ

27.930USD

-1.790-6.02%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

796.01MMarket Cap

LossP/E TTM



LENZ Therapeutics Inc

27.930

-1.790-6.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of LENZ Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LENZ Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

208 / 501

Overall Ranking

365 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

53.429

Target Price

+79.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

LENZ Therapeutics Inc Highlights

StrengthsRisks

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Undervalued

The company’s latest PE is -19.24, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 30.36M shares, increasing 3.24% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 14.61K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.11.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

LENZ Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.08, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -19.24, which is -352.05% below the recent high of 48.49 and -56.76% above the recent low of -30.16.

Score

Industry at a Glance

Previous score

7.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 208/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for LENZ Therapeutics Inc is 53.00, with a high of 67.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

53.429

Target Price

+79.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

LENZ Therapeutics Inc

LENZ

Apple Inc

AAPL

GE Vernova Inc

GEV

Tapestry Inc

TPR

Avantor Inc

AVTR

FMC Corp

FMC

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.68, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 44.26 and the support level at 24.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.72

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.662

Sell

RSI(14)

26.233

Sell

STOCH(KDJ)(9,3,3)

8.114

Oversold

ATR(14)

2.475

Low Volatility

CCI(14)

-106.569

Sell

Williams %R

94.773

Oversold

TRIX(12,20)

-1.403

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

29.912

Sell

MA10

31.046

Sell

MA20

36.266

Sell

MA50

39.554

Sell

MA100

36.266

Sell

MA200

30.917

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 106.45%, representing a quarter-over-quarter increase of 1.93%. The largest institutional shareholder is The Vanguard, holding a total of 1.29M shares, representing 4.52% of shares outstanding, with 5.77% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

4.18M

Alpha Wave Global, LP

3.61M

Versant Ventures

2.88M

-4.48%

Ridgeback Capital Management, L.P.

1.95M

Paradigm BioCapital Advisors LP

1.72M

+20.93%

The Vanguard Group, Inc.

Star Investors

1.29M

+7.65%

BlackRock Institutional Trust Company, N.A.

1.27M

+20.60%

Adage Capital Management, L.P.

1.12M

+108.79%

72 Investment Holdings, LLC

1.02M

Sectoral Asset Management Inc.

977.25K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.